publication antihypertensive lipid- lowering treatment prevent heart attack trial allhat role peripheral alpha- 1 antagonist treatment hypertension have become controversial. doxazosin arm allhat be stop early due doubling incidence congestive heart failure group compare low-dose chlorthalidone arm [ 1 ]. prior publication have be obvious suggestion mechanism peripheral alpha- 1 antagonist general doxazosin particular be inferior chlorthalidone specifically cause chf. allhat be active-control trial inference be make increase incidence chf result harmful effect doxazosin beneficial effect chlorthalidone. nonetheless have be large body literature dedicate positive effect peripheral alpha- 1 antagonist surrogate endpoint such cholesterol level tolerability. light result allhat perform review literature doxazosin terazosin prazosin. medline cochrane database be use identify english-language papers peripheral alpha- 1 antagonist study target cardiovascular endpoint background physiologic literature study suggest mechanism lead inferior performance cardiovascular endpoint. medline be search 1966 present key word doxazosin prazosin terazosin adrenergic alpha-antagonist alpha blocker. search be then limit clinical trial have hypertension key word. study be include review address one combination three agent main focus context hypertension therapy way address outcome interest note. relevant datum study be report descriptively. other relevant reference be acquire bibliographic search. use hypertension prostatism evidence suggest alpha- 1 antagonist be frequently prescribe hypertension be few publish datum concern prevalence routine use peripheral alpha- 1 antagonist prevalence accord co-morbid condition such benign prostatic hypertrophy usual duration therapy. sixth report joint national committee prevention detection evaluation treatment high blood pressure jnc vus peripheral alpha- 1 antagonist be recommend not only second-line anti-hypertensive therapy low-dose diuretic beta blocker also specific indication such therapy man hypertension prostatism [ 2 ]. alpha- 1 antagonist represent effective therapy prostatism fifty percent man have histologic evidence bph 60 year age [ 3 4 ]. national ambulatory medical care survey report number people type peripheral alpha- 1 antagonist 1995 be approximately 6 7 % hypertension [ 5 ]. 80 % survey physician choose drug first-line blood pressure agent patient hypertension symptom bph [ 6 ]. peripheral alpha- 1 antagonist be consistently associate fluid retention. 1984 study prazosin report bauer reveal increase plasma volume interstitial fluid volume extracellular fluid volume follow short-term long-term therapy [ 7 ]. study 14 hypertensive man be significant 1 4 l average increase ecfv 200 ml average increase plasma volume measure radioisotopic assay occur 3. 6 week initiation last 5 6 month chronic therapy be still present two-week washout period. be weight change study two other study demonstrate increase weight as well laboratory change consistent volume expansion prazosin [ 8 9 ]. bauer colleague suggest net increase total body sodium acute renal effect prazosin be offset decrease actual body weight. also demonstrate fractional excretion sodium be unchanged treatment further suggest acute change be follow chronic sodium homeostasis maintenance increase total body sodium. va cooperative study antihypertensive agent be double-blind randomized controll trial compare atenolol captopril clonidine diltiazem hydrochlorothiazide prazosin placebo difference antihypertensive efficacy 1 105 man have mild diastolic hypertension [ 10 ]. highly significant weight gain 1 kilogram be observe 8 week prazosin compare baseline p &lt; 001 gain be also statistically significant compare 8. week weight change other group have experience weight loss mean weight change p &lt; 0 05. prazosin arm have highest rate adverse effect lead discontinuation treatment. termination rate 13 8 % be higher termination rate adverse effect clonidine 10 % significantly higher rate captopril 4 8 % atenolol 2 % hydrochlorothiazide 1 % [ 11 ]. number man treat prazosin decrease 62 beginning trial 28 end. average weight gain 0 5 kilogram baseline be no longer statistically significant one year therapy compare original baseline weight other therapy. safety tolerability trial terazosin have show similar result table. patient treat terazosin tend gain 1 kilogram baseline active therapy trial placebo therapy lose weight. two randomized trial include phase withdrawal active therapy weight information report ruoff [ 12 ]. withdrawal active therapy be associate loss 1 3 kilogram. doxazosin have also be associate volume expansion. physiology study report lund- johansen demonstrate plasma volume fluid expansion 10 % compare baseline value [ 13 ]. larger randomized controll trial have also consistently demonstrate patient treat doxazosin gain weight summarize table 2. patient treat doxazosin tend gain weight patient placebo therapy lose weight. treatment mild hypertension study tomh trial be notable exception trend weight gain [ 14 ]. five treatment group placebo group receive intensive dietary counseling aim weight loss group lose weight significant difference trial arm. physiologic study small number participant be nature underpowered detect meaningful population difference provide starting point such datum be not available. peripheral alpha- 1 antagonist be associate perturbation neurohormonal level various study. particular peripheral alpha- 1 antagonist be associate increase plasma norepinephrine diverse patient population summarize table 3. table reflect increase norepinephrine normotensive patient hypertensive patient patient chronic congestive heart failure variety small study. several line evidence suggest elevated catecholamine level be cardiotoxic [ 15 ]. elevated plasma norepinephrine level be hypothesize cause direct myocardial damage many mechanism be amplify concomitant alpha- 1 blockade. rat norepinephrine stimulate apoptosis be mediated beta receptor [ 16 ]. addition alpha- 1 cardiac receptor inhibit response rat myocyte [ 17 ]. increase concentration norepinephrine lead cardiac beta receptor stimulation combine alpha- 1 receptor inhibition lead increase apoptosis myocyte. other hormone be associate cardiovascular disease be affect peripheral alpha- 1 antagonist. endothelin- 1 be vascular hormone play role generation maintenance heart failure [ 18 ]. hypertensive patient doxazosin lower von willebrand factor commensurate blood pressure do not lower high level endothelin- 1 atenolol do [ 19 ]. other mechanism cellular injury have be suggest. hooper propose peripheral alpha- 1 antagonist alter cellular repair mechanism possibly cause cardiac damage. note prazosin block heat shock protein expression myocardium have be hypothesize leave myocardium more vulnerable injury [ 20 ]. 1966 2001 be 188 publish cardiovascular randomized controll trial relate treatment hypertension use peripheral alpha- 1 antagonist. only allhat specifically assess difference cardiovascular endpoint result control hypertension peripheral alpha- 1 antagonist. most trial focus surrogate endpoint such equivalence blood-pressure reduction effect cholesterol. other study focus tolerability pharmacology. be case control cohort other study analyze impact agent cardiovascular endpoint. use datum other trial offer partial framework interpretation newer finding. allhat demonstrate highly statistically significant double incidence heart failure doxazosin arm compare heart failure occurrence chlorthalidone arm. be difference primary outcome chd secondary outcome total mortality be small statistically significant increase secondary outcome angina rr 1 16 95 % cus 1 05. 1 27 stroke rr 1 19 95 % cus 1 01. 1 40. allhat be comparative trial know doxazosin be associate more adverse cardiovascular outcome low-dose chlorthalidone do not know doxazosin compare placebo. shep trial however do provide comparison chlorthalidone placebo therapy reference point heart failure study population have different demographic blood pressure distribution [ 21 ]. shep trial include 4 736 people age 60 older have systolic blood pressure 160 219 mmhg diastolic blood pressure less 90 mmhg. subject be randomized low-dose diuretic placebo be follow average 4 5 year major cv event. comparison randomized active therapy placebo demonstrate nearly 50 % reduction fatal nonfatal heart failure event rr 0 51 95 % cus 0 37. 0 71. rate chf shep participant treat diuretic placebo be 5 10 1 000 person-year respectively. comparison rate chf allhat participant treat diuretic doxazosin be 10 20 1 000 person-year respectively. low-dose chlorthalidone have similar risk reduction allhat population halve incidence clinical heart failure event compare therapy effect doxazosin be comparable placebo arm shep trial. report doxazosin arm termination allhat be publish april 2000. time result allhat trial be unexpected give potential association high dose diuretic risk sudden death [ 22 ] favorable effect peripheral alpha- 1 antagonist lipid profile [ 14 ]. compare datum other study suggest possibility beneficial effect peripheral alpha- 1 antagonist lower blood pressure be nullify negative effect other antihypertensive have positive action antihypertensive effect. treat doxazosin allhat have mean blood pressure be 2 3 mmhg higher mean blood pressure treat chlorthalidone. base framingham heart study logistic regression coefficient 2 3 mmhg difference systolic blood pressure be associate increase relative risk only 1 06 1 09 [ 23 ]. available datum appear average difference systolic blood pressure be not large enough double average incidence chf. literature suggest several mechanism peripheral alpha- 1 antagonist general doxazosin particular prove inferior other type antihypertensive therapy. be associate mild volume expansion precipitate clinical presentation heart failure subclinical disease. be mechanism responsible increase incidence chf allhat trial be consistent early divergence kaplan- meier curve study. peripheral alpha- 1 antagonist also cause neurohormonal change chronic therapy. long-term ramification change patient be treat hypertension be not know. drug appear cause increase norepinephrine increase nullify beneficial effect lower blood pressure occurrence chf. not only be increase plasma catecholamine central feature heart failure be now recommend target effective life-prolonging therapy [ 24 25 26 ]. give doxazosin be not as effective chlorthalidone reduce cardiovascular complication hypertension several question remain. be still paucity information regard absolute risk reduction clinical heart failure other cardiovascular event afford peripheral alpha- 1 antagonist variety population. differentiation mechanism reduce protection compare diuretic be interesting difficult accomplish. heart failure particular increase symptomatic episode chf be due hemodynamic effect doxazosin unmask incipient heart failure direct myocardial injury. chronic volume loading not only unmask subclinical ventricular dysfunction possibly contribute worsen ventricular function time. mechanism be responsible heart failure finding allhat result support current national recommendation use low-dose diuretic beta-blocker first line agent pharmacologic treatment uncomplicated hypertension